Overview

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Status:
Completed

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or metastatic breast cancer who have not received chemotherapy or have received one non-taxane based chemotherapy for metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Geron Corporation

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Imetelstat
Motesanib diphosphate
Niacinamide
Paclitaxel